Breaking
A woman who says she nearly died after taking abortion pills is urging Health and Human Services Secretary Robert F. Kennedy Jr. to crack down on mail-order access to the drugs, Fox News Digital reported Thursday. Haile McAnally warned that shipping the pills directly to women’s homes is “reckless” and could put more lives at risk.
McAnally is speaking out in response to a Nov. 6 letter from Susan B. Anthony (SBA) Pro-Life America calling on Kennedy to immediately restore in-person dispensing requirements for mifepristone while the Food and Drug Administration conducts a safety review. “Mailing them across the country to doorsteps just as easily as you could an Amazon package is not only reckless, it puts a lot of women’s lives and safety at risk,” McAnally told Fox News Digital.
Details & Background
McAnally, who serves as communications director for the Nebraska Republican Party and works with SBA Pro-Life America on legislation, said she suffered severe bleeding and required a blood transfusion after taking abortion pills 14 years ago. “When I took these pills at a clinic and ended up having severe side effects, I wound up alone in my bathtub, almost dying from these pills, needing a blood transfusion at the hospital,” she said. She first shared her experience with Fox News Digital in September. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the abortion. An April 2025 study by the conservative Ethics and Public Policy Center found that 10.93% of women “experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following a mifepristone abortion.”
SBA argues that Kennedy already has the legal authority to act. The group points to a Justice Department filing earlier this year that it says confirms Kennedy could reverse the Biden administration’s 2023 changes allowing mifepristone to be dispensed by mail. “Secretary Kennedy, you possess clear statutory authority to protect women from this growing form of abuse,” the letter reads. The fight is further complicated by the White House’s reported decision to pull Heidi Overton’s nomination to lead the FDA.
Reactions
Erik Baptist, senior vice president of legal strategy at SBA Pro-Life America, said the group wants commitments from the next FDA nominee. “Now that the White House has pulled Heidi Overton’s nomination, we look forward to meeting with the administration’s new nominee for FDA Commissioner. We hope to secure two fundamental commitments on abortion-drug policy before the Senate proceeds with any confirmation vote,” Baptist told Fox News Digital. “The administration must immediately end the Biden FDA’s mail-order abortion-drug scheme and protect pregnant women from predators who coerce or poison women with these drugs,” he continued, adding, “Confirmation is not a coronation.”
McAnally urged federal officials to weigh the risks. “I just continue to urge the federal government, especially RFK Jr. and the senators … to make sure that we really think about the ramifications of letting this go through so easily,” she said. “Life is precious. Women’s lives are precious, and women’s safety deserves the utmost importance when it comes to this issue.” Fox News Digital reached out to Kennedy and the White House for comment.
Why This Matters to You
The decision now in Kennedy’s hands affects how a widely used drug reaches American homes. Since the Biden administration’s 2023 changes, mifepristone can be dispensed by mail. SBA wants in-person dispensing restored while the FDA finishes its safety review, and the group says federal law lets the HHS secretary suspend drug approvals immediately if he finds an imminent hazard to public health.
The timing adds pressure. With the White House reportedly dropping Overton’s nomination, SBA says it wants commitments on abortion-drug policy from the next FDA nominee before the Senate proceeds with any confirmation vote. “We’re asking that we put a stop to these mail-order abortion drugs and not only for more research into mifepristone and the side effects, but just because the recklessness and the side effects that these have,” McAnally said. How Kennedy responds will signal where the administration stands on one of the most closely watched health policy fights of the year.